SXTC
China SXT Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
SXTC fundamentals
During H1 2026, China SXT Pharmaceuticals (SXTC) reported revenue of 626.57K, a YoY change of -24.46%. Net income was -6.37M, a YoY change of -693.55%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2016 | 9M,2017 | FY,2017 | H1,2018 | 9M,2018 | FY,2018 | H1,2019 | FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | H1,2026 | TTM |
|---|
Start Date | Apr 1, 2015 | Apr 1, 2016 | Apr 1, 2016 | Apr 1, 2017 | Apr 1, 2017 | Apr 1, 2017 | Apr 1, 2018 | Apr 1, 2018 | Apr 1, 2019 | Apr 1, 2019 | Apr 1, 2020 | Apr 1, 2020 | Apr 1, 2021 | Apr 1, 2021 | Apr 1, 2022 | Apr 1, 2022 | Apr 1, 2023 | Apr 1, 2023 | Apr 1, 2024 | Apr 1, 2024 | Apr 1, 2025 | -- |
End Date | Mar 31, 2016 | Dec 31, 2016 | Mar 31, 2017 | Sep 30, 2017 | Dec 31, 2017 | Mar 31, 2018 | Sep 30, 2018 | Mar 31, 2019 | Sep 30, 2019 | Mar 31, 2020 | Sep 30, 2020 | Mar 31, 2021 | Sep 30, 2021 | Mar 31, 2022 | Sep 30, 2022 | Mar 31, 2023 | Sep 30, 2023 | Mar 31, 2024 | Sep 30, 2024 | Mar 31, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | -- |
Revenue | 3.72M -- | 3.73M -- | 4.88M +31.27% | 3.89M -- | 5.59M +49.78% | 7.02M +43.79% | 3.92M +0.72% | 7.01M -0.10% | 3.22M -17.93% | 5.16M -26.38% | 3.86M +20.07% | 4.78M -7.45% | 1.03M -73.38% | 2.60M -45.53% | 1.21M +17.58% | 1.97M -24.23% | 939.58K -22.24% | 1.93M -2.19% | 829.49K -11.72% | 1.74M -9.73% | 626.57K -24.46% | 1.54M -- |
Sales and Services Revenue | 3.72M -- | 3.73M -- | 4.88M +31.27% | 3.89M -- | 5.59M +49.78% | 7.02M +43.79% | 3.92M +0.72% | 7.01M -0.10% | 3.22M -17.93% | 5.16M -26.38% | 3.86M +20.07% | 4.78M -7.45% | 1.03M -73.38% | 2.60M -45.53% | 1.21M +17.58% | 1.97M -24.23% | 939.58K -22.24% | 1.92M -2.86% | 829.49K -11.72% | 1.70M -11.20% | 626.57K -24.46% | 1.50M -- |
Other Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 13.15K -- | -- -- | 40.02K +204.37% | -- -- | -- -- |
Cost of Revenue | 2.92M -- | 2.04M -- | 2.57M -12.14% | 2.23M -- | 3.00M +47.14% | 3.62M +40.79% | 1.24M -44.48% | 2.40M -33.65% | 1.38M +11.04% | 2.46M +2.42% | 1.04M -24.44% | 1.94M -21.17% | 703.72K -32.31% | 1.35M -30.31% | 1.12M +58.96% | 1.55M +14.42% | 651.24K -41.78% | 1.37M -11.06% | 694.74K +6.68% | 1.37M -0.08% | 524.85K -24.45% | 1.20M -- |
Cost of Goods and Services | -- -- | -- -- | 2.57M -- | -- -- | -- -- | 3.62M +40.79% | -- -- | 2.40M -33.65% | -- -- | 2.46M +2.42% | -- -- | 1.94M -21.17% | -- -- | 1.35M -30.31% | -- -- | 1.55M +14.42% | 651.24K -- | 1.37M -11.06% | 694.74K +6.68% | 1.37M -0.08% | 524.85K -24.45% | 1.20M -- |
Gross Profit | 793.99K -- | 1.69M -- | 2.31M +191.19% | 1.66M -- | 2.59M +52.95% | 3.40M +47.12% | 2.68M +61.56% | 4.61M +35.57% | 1.84M -31.33% | 2.70M -41.37% | 2.82M +53.36% | 2.84M +5.02% | 323.96K -88.52% | 1.25M -55.92% | 89.68K -72.32% | 426.27K -65.94% | 288.34K +221.51% | 553.97K +29.96% | 134.75K -53.27% | 367.43K -33.67% | 101.72K -24.51% | 334.39K -- |
Operating Expenses | 584.85K -- | 598.49K -- | 709.82K +21.37% | 611.37K -- | 1.26M +110.07% | 1.77M +149.25% | 1.35M +121.10% | 2.84M +60.64% | 2.06M +52.41% | 4.04M +42.32% | 1.66M -19.56% | 5.04M +24.52% | 3.22M +94.04% | 6.44M +27.89% | 1.24M -61.43% | 6.03M -6.33% | 9.64M +677.13% | 3.07M -49.13% | 773.02K -91.98% | 3.05M -0.69% | 6.44M +733.18% | 8.72M -- |
Selling, General and Administrative Expenses | 584.85K -- | 598.49K -- | 709.82K +21.37% | 611.37K -- | 1.26M +110.07% | 1.77M +149.25% | 1.35M +121.10% | 2.84M +60.64% | 2.06M +52.41% | 4.04M +42.32% | 1.66M -19.56% | 5.04M +24.52% | 3.22M +94.04% | 6.44M +27.89% | 1.24M -61.43% | 6.03M -6.33% | 9.64M +677.13% | 3.07M -49.13% | 773.02K -91.98% | 3.05M -0.69% | 6.44M +733.18% | 8.72M -- |
Selling and Marketing Expenses | -- -- | -- -- | 144.36K -- | -- -- | -- -- | 512.48K +254.99% | -- -- | 1.61M +213.28% | -- -- | 1.58M -1.38% | -- -- | 1.59M +0.26% | -- -- | 924.54K -41.76% | -- -- | 387.45K -58.09% | 176.95K -- | 433.57K +11.90% | 50.62K -71.39% | 289.86K -33.15% | 38.62K -23.70% | 277.86K -- |
General and Administrative Expenses | -- -- | -- -- | 565.46K -- | -- -- | -- -- | 1.26M +122.25% | -- -- | 1.24M -1.61% | -- -- | 2.46M +99.07% | -- -- | 3.45M +40.13% | -- -- | 5.52M +59.94% | -- -- | 5.65M +2.35% | 9.46M -- | 2.64M -53.32% | 722.40K -92.36% | 2.76M +4.65% | 6.40M +786.22% | 8.44M -- |
Operating Income | 209.14K -- | 1.09M -- | 1.60M +666.08% | 1.05M -- | 1.33M +21.72% | 1.63M +1.88% | 1.33M +26.78% | 1.77M +8.41% | -220.75K -116.64% | -1.34M -175.79% | 1.16M +627.20% | -2.20M -63.82% | -2.89M -348.45% | -5.19M -136.21% | -1.15M +60.21% | -5.61M -8.05% | -9.35M -712.64% | -2.52M +55.15% | -638.27K +93.17% | -2.68M -6.57% | -6.34M -893.15% | -8.38M -- |
Non-Operating Income (Loss) | -20.42K -- | -14.08K -- | -21.99K -7.69% | 3.10K -- | 8.73K +162.03% | -4.58K +79.16% | 517 -83.32% | 21.97K +579.42% | -2.13M -412572.34% | -9.05M -41291.23% | 452.46K +121.22% | -743.79K +91.78% | 125.48K -72.27% | -218.28K +70.65% | -344.16K -374.27% | -327.26K -49.93% | -347.14K -0.86% | -583.32K -78.24% | -164.30K +52.67% | -623.17K -6.83% | -29.88K +81.82% | -488.75K -- |
Other Non-Operating Income (Loss) | 30.64K -- | 13.06K -- | 18.40K -39.94% | 3.40K -- | 8.24K -36.87% | -3.80K -120.67% | -984 -128.95% | 27.14K +813.67% | 38.08K +3969.82% | -5.70M -21100.28% | 894.54K +2249.18% | 871.65K +115.29% | 125.41K -85.98% | -181.58K -120.83% | 40.12K -68.01% | 149.51K +182.34% | -10.62K -126.46% | -39.04K -126.11% | 18.17K +271.15% | 25.05K +164.17% | 1.45K -92.04% | 8.32K -- |
Net Interest Expense | 51.06K -- | 27.14K -- | 40.39K -20.90% | 300 -- | -490 -101.81% | 779 -98.07% | -1.50K -600.33% | 5.17K +564.18% | 2.17M +144707.66% | 3.35M +64623.42% | 442.08K -79.63% | 1.62M -51.76% | -69 -100.02% | 36.70K -97.73% | 384.29K +557036.23% | 476.78K +1199.29% | 336.52K -12.43% | 544.28K +14.16% | 182.47K -45.78% | 648.22K +19.10% | 31.32K -82.83% | 497.07K -- |
Interest Income | -- -- | -27.14K -- | -- -- | -- -- | 490 +101.81% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | 188.72K -- | 1.08M -- | 1.58M +737.30% | 1.05M -- | 1.34M +24.11% | 1.63M +3.01% | 1.33M +26.46% | 1.79M +10.06% | -2.35M -277.27% | -10.39M -679.95% | 1.62M +168.68% | -2.94M +71.69% | -2.77M -271.14% | -5.41M -83.89% | -1.49M +45.97% | -5.93M -9.74% | -9.70M -548.74% | -3.10M +47.79% | -802.57K +91.72% | -3.30M -6.62% | -6.37M -693.55% | -8.87M -- |
Income Tax Expense | 47.18K -- | 270.11K -- | 395.05K +737.31% | 262.44K -- | 335.24K +24.11% | 440.10K +11.40% | 332.41K +26.66% | 252.23K -42.69% | -5.17K -101.55% | -101.72K -140.33% | 235.02K +4649.28% | -192.68K -89.42% | 325.78K +38.62% | 328.15K +270.30% | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Current Income Tax | -- -- | -- -- | 395.05K -- | -- -- | -- -- | 445.95K +12.89% | -- -- | 259.95K -41.71% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -5.85K -- | -- -- | -7.72K -31.99% | -- -- | -101.72K -1217.13% | -- -- | -192.68K -89.42% | -- -- | 328.15K +270.30% | -- -- | 0 -100.00% | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- |
Net Income | 141.54K -- | 810.34K -- | 1.19M +737.30% | 787.30K -- | 1.01M +24.11% | 1.19M +0.21% | 995.05K +26.39% | 1.54M +29.61% | -2.35M -335.98% | -10.29M -768.38% | 1.38M +158.83% | -2.75M +73.29% | -3.09M -323.84% | -5.74M -108.72% | -1.49M +51.66% | -5.93M -3.46% | -9.70M -548.74% | -3.10M +47.79% | -802.57K +91.72% | -3.30M -6.62% | -6.37M -693.55% | -8.87M -- |
Net Income Attributable to Owners of the Company | 141.54K -- | 810.34K -- | 1.19M +737.30% | 787.30K -- | 1.01M +24.11% | 1.19M +0.21% | 995.05K +26.39% | 1.54M +29.61% | -2.35M -335.98% | -10.29M -768.38% | 1.38M +158.83% | -2.75M +73.29% | -3.09M -323.84% | -5.74M -108.72% | -1.49M +51.66% | -5.93M -3.46% | -9.70M -548.74% | -3.10M +47.79% | -802.57K +91.72% | -3.30M -6.62% | -6.37M -693.55% | -8.87M -- |
Net Income Attributable to Common Stockholders | 141.54K -- | 810.34K -- | 1.19M +737.30% | 787.30K -- | 1.01M +24.11% | 1.19M +0.21% | 995.05K +26.39% | 1.54M +29.61% | -2.35M -335.98% | -10.29M -768.38% | 1.38M +158.83% | -2.75M +73.29% | -3.09M -323.84% | -5.74M -108.72% | -1.49M +51.66% | -5.93M -3.46% | -9.70M -548.74% | -3.10M +47.79% | -802.57K +91.72% | -3.30M -6.62% | -6.37M -693.55% | -8.87M -- |
Other Comprehensive Income | -35.22K -- | -84.07K -- | -75.27K -113.74% | 2.33K -- | 141.75K +268.62% | 245.55K +426.24% | 321.07K +13662.28% | -206.98K -184.29% | -807.32K -351.44% | -641.05K -209.72% | 638.77K +179.12% | 1.12M +274.47% | 231.03K -63.83% | 428.36K -61.70% | -1.74M -851.20% | -1.15M -369.34% | -821.24K +52.68% | -828.22K +28.21% | 456.94K +155.64% | -49.73K +94.00% | 308.53K -32.48% | -198.14K -- |
Total Comprehensive Income | 106.33K -- | 726.27K -- | 1.11M +943.82% | 789.64K -- | 1.15M +57.99% | 1.43M +29.12% | 1.32M +66.67% | 1.33M -7.04% | -3.16M -339.75% | -10.93M -920.34% | 2.02M +164.02% | -1.63M +85.09% | -2.86M -241.62% | -5.31M -225.68% | -3.23M -12.91% | -7.09M -33.55% | -10.52M -225.60% | -3.93M +44.60% | -345.63K +96.71% | -3.35M +14.60% | -6.06M -1653.42% | -9.07M -- |
Total Comprehensive Income Attributable to Owners of the Company | 106.33K -- | 726.27K -- | 1.11M +943.82% | 789.64K -- | 1.15M +57.99% | 1.43M +29.12% | 1.32M +66.67% | 1.33M -7.04% | -3.16M -339.75% | -10.93M -920.34% | 2.02M +164.02% | -1.63M +85.09% | -2.86M -241.62% | -5.31M -225.68% | -3.23M -12.91% | -7.09M -33.55% | -10.52M -225.60% | -3.93M +44.60% | -345.63K +96.71% | -3.35M +14.60% | -6.06M -1653.42% | -9.07M -- |
Basic EPS | 0.01 -- | 0.04 -- | 0.06 +500.00% | 0.04 -- | 0.05 +25.00% | 0.06 -- | 0.05 +25.00% | 0.3 +400.00% | -0.1 -300.00% | -33.28 -11193.33% | 0.1 +200.00% | -3.82 +88.52% | -3.98 -4080.00% | -137.92 -3510.47% | -14.61 -267.09% | -177.84 -28.94% | -19.34 -32.38% | -28.58 +83.93% | -0.25 +98.71% | -2.32 +91.88% | -0.06 +76.00% | -2.13 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | 0.06 -- | -- -- | -- -- | 0.06 -- | -- -- | 0.3 +400.00% | -- -- | -33.28 -11193.33% | -- -- | -3.82 +88.52% | -- -- | -137.92 -3510.47% | -- -- | -177.84 -28.94% | -19.34 -- | -28.58 +83.93% | -0.25 +98.71% | -2.32 +91.88% | -0.06 +76.00% | -2.13 -- |
Diluted EPS | 0.01 -- | 0.04 -- | 0.06 +500.00% | 0.04 -- | 0.05 +25.00% | 0.06 -- | 0.05 +25.00% | 0.3 +400.00% | -0.1 -300.00% | -33.28 -11193.33% | 0.1 +200.00% | -3.82 +88.52% | -3.98 -4080.00% | -137.92 -3510.47% | -14.61 -267.09% | -177.84 -28.94% | -19.34 -32.38% | -28.58 +83.93% | -0.25 +98.71% | -2.32 +91.88% | -0.06 +76.00% | -2.13 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | 0.06 -- | -- -- | -- -- | 0.06 -- | -- -- | 0.3 +400.00% | -- -- | -33.28 -11193.33% | -- -- | -3.82 +88.52% | -- -- | -137.92 -3510.47% | -- -- | -177.84 -28.94% | -19.34 -- | -28.58 +83.93% | -0.25 +98.71% | -2.32 +91.88% | -0.06 +76.00% | -2.13 -- |
You can ask Aime
What is the market's earnings forecast for China SXT Pharmaceuticals next quarter?What is the revenue and EPS growth rate for China SXT Pharmaceuticals year over year?What is China SXT Pharmaceuticals's gross profit margin?What guidance did China SXT Pharmaceuticals's management provide for the next earnings period?What factors drove the changes in China SXT Pharmaceuticals's revenue and profit?What were the key takeaways from China SXT Pharmaceuticals’s earnings call?Did China SXT Pharmaceuticals beat or miss consensus estimates last quarter?What is China SXT Pharmaceuticals's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
